MedTrace Logo

Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda

NCT00489658 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2007-06-21

No results posted yet for this study

Summary

This case series study follows on a terminated randomised clinical trial in a nearby location of Uganda, in which the combination of eflornithine + nifurtimox showed very promising efficacy and safety. The study's purpose is to evaluate the efficacy and safety of this combination in a larger group of late-stage Human African trypanosomiasis (sleeping sickness) patients.

Conditions

  • Trypanosomiasis, African

Interventions

DRUG

Eflornithine plus Nifurtimox combination therapy

Sponsors & Collaborators

  • Médecins Sans Frontières, France

    collaborator OTHER

  • Epicentre

    lead OTHER

Principal Investigators

  • Patrice Piola, MD MSc · Epicentre

  • Gerardo Priotto, MD MPH · Epicentre

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00489658 on ClinicalTrials.gov